Simultaneous spectrophotometric determination of recombined sofosbuvir, ledipasvir and paracetamol together as commonly repurposed drugs for COVID-19 treatment

Author:

Gamal SherifORCID,Mandour Asmaa A.,Mohamed Gehad G.,Salih Said A.,Ahmed Dina A.

Abstract

Abstract Background COVID-19 has emerged as the most serious outbreak in recent years. Certain medications such as sofosbuvir (SOF), ledipasvir (LDV) and paracetamol (PAR) were proposed as a safer and recommended substance to control symptoms of COVID-19. Results Using built-in spectrophotometer software, zero order and derivative spectra of the studied components, two extremely clear, quick, and sensitive spectrophotometric techniques for simultaneous determinations of SOF, LDV, as well as PAR have been developed. LDV was calculated using a zero order absorption spectrum at wavelength maxima of 333 nm. SOF and PAR were evaluated simultaneously using a first derivative spectrophotometer at 247.2 nm and 260.8 nm, respectively. The calibration graphs for SOF, LDV, and PAR are linear over ranges of concentrations of 8–60 µg/mL, 4–22 µg/mL, and 2–14 µg/mL, consequently. The suggested methodologyspecificity was investigated using laboratory manufactured (different ratios) mixtures, which were then effectively used to the analysis of Mpiviropack plus® and Panadol® pills. Valid limitations included accuracy, precision, and specificity. The methodologies were validated in accordance with some ICH standards. Conclusions The methods proposed were simple, accurate, precise, and neither require any complex equipment nor specific software.

Publisher

Springer Science and Business Media LLC

Subject

General Medicine

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3